Where the Deals are...Cancer Remains Hot

Tracking dealmaking in biopharma is more than a pastime, of course. Discerning trends is necessary for knowing where to focus and when to strike. And so a new analysis by Deloitte of hundreds of deals last year, which involved products and platform technologies, may provide some clues as to where the money and work will be directed going forward. The report looked at 714 licensing deals and joint ventures, although only 245 disclosed deal size or upfront payments.